Dompé is a major Italian biopharmaceutical company, engaged in research, development and the production of therapeutic solutions.
Prescription drugs and OTC products, dietary supplements, medical devices and cosmetics
Treatment of rare diseases with no approved treatment
Pain and inflammation, respiratory, diabetology, well-being, integration
Revenues in euros (2019)
Europe, United States, China
Packages manufactured in 2019
Production lines (7 synthesis, 1 biotech)
Synthesis and biotech
EMA (European Medicines Agency), Europe
FDA (Food and Drug Administration), United States
We have developed the first treatment based on rhNGF (recombinant human Nerve Growth Factor) for neurotrophic keratitis, a rare eye disease previously with no approved treatment.
The marketing authorization for this treatment has been granted by some international regulatory authorities, such as the EMA and the FDA.
Year of marketing authorization granted by the EMA in Europe
Year of marketing authorization granted by the FDA in the United States, following the Fast Track, Breakthrough Therapy Designation and Priority Review designations
Inclusion among the 40 active principles of prioritary interest for China
Expected CFDA (Chinese Food and Drug Administration) marketing authorization
Dompé farmaceutici is established in 1940, stemming from a pharmacological tradition dating back to the Nineteenth Century
Gian Antonio Dompé devotes himself to studying chemical-pharmaceutical sciences and eventually becomes a science savant.
Onorato Dompé, Gian Antonio’s son, establishes the Dompé-Adami laboratory in Milan.
Onorato Dompé establishes the first pharmaceutical production plant in Milan.
Franco Dompé, Onorato’s son, founds Dompé farmaceutici in Milan.